Innate Pharma S.A. (IPHA)
NASDAQ: IPHA · IEX Real-Time Price · USD
2.400
-0.050 (-2.04%)
Apr 25, 2024, 4:00 PM EDT - Market closed

Innate Pharma Balance Sheet

Millions EUR. Fiscal year is Jan - Dec.
Year 2023202220212020201920182017
Cash & Equivalents
70.6184.23103.76136.79202.89152.3199.37
Short-Term Investments
21.8517.2616.0814.8515.9815.2216.74
Cash & Cash Equivalents
92.46101.49119.84151.64218.87167.53116.11
Cash Growth
-8.90%-15.31%-20.97%-30.72%30.64%44.29%-
Receivables
66.1152.4548.2451.6435.48152.1121.41
Other Current Assets
-10.56-14.1-29.82-29.82-16.740-0
Total Current Assets
148.01139.83138.26173.45237.61319.64137.52
Property, Plant & Equipment
6.328.5410.1711.6911.6710.2210.73
Long-Term Investments
9.835.1239.8838.9337.0135.1860.47
Goodwill and Intangibles
0.421.5644.1946.2996.9784.5346.19
Other Long-Term Assets
19.6522.823537.0618.111.650.11
Total Long-Term Assets
36.1868.03129.24133.97163.76131.57117.5
Total Assets
184.19207.86267.5307.42401.36451.22255.02
Accounts Payable
17.0220.9128.5729.5449.591.6624.66
Deferred Revenue
10.4814.4837.9143.9789.11150.19134.91
Current Debt
8.942.130.752.142.131.351.34
Other Current Liabilities
3.23.84-17.35-30.17-18.92-46.46-87.01
Total Current Liabilities
39.6441.3479.8945.49121.82196.7473.91
Long-Term Debt
30.9640.1513.516.9516.593.184.52
Other Long-Term Liabilities
61.772.2366.6789.0145.5384.0690.64
Total Long-Term Liabilities
92.66112.3780.17105.9662.1287.2495.16
Total Liabilities
132.29153.71160.06151.45183.95283.98169.07
Total Debt
39.8942.2544.2519.0918.724.525.86
Debt Growth
-5.58%-4.52%131.84%1.94%314.04%-22.89%-
Retained Earnings
-336.89-330.32-272.21-220.46-155.67-134.79-151.98
Shareholders' Equity
51.954.15107.44155.98217.42167.2485.96
Net Cash / Debt
52.5659.2375.59132.55200.14163.01110.25
Net Cash / Debt Growth
-11.26%-21.63%-42.98%-33.77%22.78%47.86%-
Net Cash Per Share
-----2.772.03
Working Capital
108.3898.4958.37127.96115.78122.9163.61
Book Value Per Share
0.650.681.361.992.912.851.58
Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).